Board
Screen
Heat
Cal
Watch
News
Blog
TV
Home
/
ADCT
Home
/
ADCT

NYSE
$1.72
$1.72

Overview

Price performance
Low
$1.63
High
$1.86
After hours. Last updated: Nov 4, 2026, 9:00 PM UTC
$
1.72
0.17 (10.97%)
Average, 50 days
$1.33
$2.46
Open
$1.63
Previous close
$1.55
52-week high
$4.98
Mar 11, 2026 (8 months ago)
52-week low
$0.78
Jun 8, 2026 (5 months ago)
120.63%

Valuation & Estimates

Earnings

Financials

Insider Trading

Peer Analysis

Insights & Activity

Market Cap
219.59M
Volume
4 304 387
Total Return (3M)
56.36%
Total Return (1Y)
-57.32%
5.08
Sector
Healthcare
Links
Tags
Healthcare
Biotechnology
NYSE
CH
Website
adctherapeutics.com
About
ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-ineligible patients with relapsed or refractory DLBCL; and a Phase I trial for relapsed or refractory non-Hodgkin lymphoma (NHL). The company's pipeline also includes camidanlumab tesirine, another ADC, which has completed Phase I development for relapsed or refractory NHL. It is additionally progressing through Phase II for relapsed or refractory Hodgkin lymphoma and Phase Ib for selected advanced solid tumors. Furthermore, ADC Therapeutics is advancing ADCT-602, currently in Phase Ia for acute lymphoblastic leukemia, alongside ADCT-601 and ADCT-901, both of which are in Phase Ia for various solid tumors. Its preclinical portfolio features ADCT-701 and ADCT-901, both aimed at solid tumors. The company maintains strategic collaboration and license agreements with entities such as Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. Founded in 2011, ADC Therapeutics S.A. has its headquarters located in Epalinges, Switzerland.

Frequently asked questions

ADCT · ADC Therapeutics S.A.

01What is ADC Therapeutics S.A. stock price today?

The current price of ADCT is $1.72 — it has increased by 10.97% since the previous close. Data as of Nov 4, 2026.

02Is ADC Therapeutics S.A. stock price growing?

ADCT is up 15.44% over the past week, up 52.21% over the past month and down 57.32% over the past year. The price is below its 200-day moving average of $2.46.

03What is ADC Therapeutics S.A. market cap?

ADC Therapeutics S.A. has a market capitalization of $219.59M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

04What were ADC Therapeutics S.A. earnings last quarter?

In its most recent quarterly report, ADC Therapeutics S.A. posted a loss of $0.11 per share against an estimate of -$0.216, beating expectations by 49.07%. Upcoming reports are listed in the earnings calendar.

05What is ADC Therapeutics S.A. revenue for the last quarter?

ADC Therapeutics S.A. reported revenue of $19.25M in its most recent quarter, which has increased by 2.17% compared with the same quarter a year earlier. Analysts had expected $18.89M.

06Who are ADC Therapeutics S.A. competitors?

Companies most comparable to ADC Therapeutics S.A. include RAPT Therapeutics, Inc., Omeros Corporation, Alumis Inc., 4D Molecular Therapeutics, Inc. and Lexicon Pharmaceuticals, Inc.

07How volatile is ADCT stock?

In the latest trading session ADCT moved between $1.63 and $1.87, a range of 13.95% of its current price.

08What are ADCT stock 52-week high and low?

Over the past 52 weeks ADCT has traded between $0.7796 and $4.98. The current price is 65.46% below its 52-week high.

Figures as of Nov 4, 2026. This information is provided for general purposes only and is not investment advice.